Chrome 2001
.
Aetna Intelihealth InteliHealth Aetna Intelihealth Aetna Intelihealth
 
.
. .
.
Chrome 2001
Chrome 2001
Health News Health News
.
Health Highlights: April 2, 2014
April 02, 2014

 

Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:

Declining U.S. Circumcision Rates Put Males' Health at Risk: Study
Nearly one-fourth of newborn boys in the United States are not being circumcised and half of them could develop health problems later in life as a result, according to a new study.
It found that circumcision rates fell from a high of 83 percent in the 1960s to 77 percent in 2010, NBC reported.
Health problems associated with an intact foreskin include bacterial and viral infections, including urinary tract infections and sexually transmitted diseases, according to study lead author Brian Morris, a professor emeritus of the School of Medical Sciences and Bosch Institute at the University of Sydney in Australia.
Males who haven't been circumcised are also at increased risk for penile and prostate cancer, NBC News reported.
The health benefits of circumcision outweigh the risks by more than 100 to 1, Morris said. The study was published Wednesday in the journal Mayo Clinic Proceedings.

-----

Inhaled Insulin Should be Approved by FDA: Advisory Panel
An inhaled insulin product to treat type 1 and type 2 diabetes should be approved for sale in the United States, a Food and Drug Administration advisory committee said Tuesday.
The panel of outside experts said that the product -- called Afrezza -- is not as effective as injected insulin but would be useful for some patients, The New York Times reported.
"As an inhaled form of insulin, this represents a drug that will serve some patients that are not effectively served by currently available insulin," the committee's acting chairman Dr. Robert Smith, an endocrinologist at Brown University, said after the vote.
The advisory panel's support for Afrezza was somewhat unexpected because an FDA staff review was critical of the product, saying it was marginally effective and possibly risky, The Times reported.
In two previous attempts, the drug failed to win FDA approval and maker MannKind Corporation had to conduct new clinical trials.
The FDA is not required to follow the advice of its advisory panels.


...

InteliHealth
.
.
.
.
.
More News
InteliHealth .
.
General Health News
Today's News
Today In Health History
This Week In Health
Addiction News
Allergy News
Alzheimer's News
Arthritis News
Asthma News
Babies News
Breast Cancer News
Bronchitis News
Cancer News
Cervical Cancer News
Children's Health News
Cholesterol News
Dental/Oral Health News
Depression News
Diabetes News
Ear, Nose And Throat News
Environmental Health News
Eye News
Fitness News
Genetics News
Headache News
Health Policy News
Heart Attack News
Heart Failure News
Heart Health News
HIV/AIDS News
Infectious Diseases News
Influenza News
Lung Cancer News
Medication News
Men's Health News
Mental Health News
Multiple Sclerosis News
Nutrition News
Parkinson's News
Pregnancy News
Prostate Cancer News
Schizophrenia
Senior Health News
Sexual/Reproductive Health News
Sexual dysfunction
Sleep News
STDs News
Stroke News
Tobacco Cessation News
Weight Management News
Women's Health News
.
.
.
.
InteliHealth
    Print Printer-friendly format    
   
.  
This website is certified by Health On the Net Foundation. Click to verify.
.